InvestorsHub Logo
Followers 12
Posts 1019
Boards Moderated 0
Alias Born 03/24/2013

Re: DewDiligence post# 17769

Monday, 10/23/2017 12:37:08 AM

Monday, October 23, 2017 12:37:08 AM

Post# of 20689
Dew, Can you please explain how MNTA could have done better at preventing TEVA from switching the patients on 40mg?

Rather, the primary blow to MNTA’s Copaxone franchise was MNTA’s unpreparedness for TEVA’s switching the market from 20mg Copaxone to 40mg. This was a business failure on MNTA’s part, not a technical failure.